KDR and central nervous system cancer: This includes therapeutic agents aimed at targets defined in adult high-grade gliomas, including platelet-derived growth factor receptor (PDGFR; Pollack et al., 2007), epidermal growth factor receptor (EGFR; Geoerger et al., 2011; Pollack et al., 2011), vascular endothelial growth factor receptor-2 (VEGFR2) (Broniscer et al., 2010), and farnesyl transferase (Haas-Kogan et al., 2011).